Logo Image
|Articles|June 27, 2019

MMS Holdings Launches New Application

MMS Holdings, a data-focused CRO, has announced the launch of Automatiqc (pronounced: automatic.) Automatiqc is a new cloud-based application that performs quality control and style checks for medical writing, pharmacovigilance, clinical trial transparency, and other types of documents in the pharmaceutical, biotechnology, and medical device industries.

This new application is customizable, enabling users to tailor the software to client style guides including journal requirements and other established guides. Automatiqc does not require special training. Automatiqc can be used for any Microsoft Word-based document type including, but not limited to:

  • Clinical Study Reports (CSRs)

  • Protocols and Investigator’s Brochures (IB)

  • Module 2 IND and NDA submission documents (M2.5, M2.7.1, M2.7.2, M2.7.3, M2.7.4, M2.7.5, and M2.7.6)

  • Module 5 Integrated Summary of Efficacy (ISE) and Integrated Summary of Safety (ISS)

  • Health Authority Responses and Response to Queries (RTQs)

  • Safety Narratives and Risk Management Plans (RMPs)

  • Publications for peer-reviewed journals and more!

This new application is currently available for use through a service relationship with MMS or licensing of the application as software-as-a-service.

For more information, visit www.mmsholdings.com

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more